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Abstract  
              Cancer is the second most common cause of death in the US. The most 
frequently observed cancer type in women is breast cancer. A special type of breast 
cancer is triple negative (TNBC) cancer that is characterized by lacking three 
receptors: estrogen, progesterone and human epithelial growth factor (HER 2). The 
HS578t breast cell line is a model of TNBC that also has a mutation of the p53 
protein.  
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            Ionizing radiation is used widely in the clinic to debulk tumors before surgery 
as well as post-surgery to eliminate residual tumor cells outside the surgical field.  
Previous studies from our laboratory showed that inhibition of autophagy does 
sensitize p53 wild type MCF-7 and ZR-75 breast tumor cells to radiation. However, 
this is not necessarily the response in all breast cell lines. The Hs578t cells did not 
appear to be sensitized to radiation after inhibition of autophagy using chloroquine 
as a pharmacological inhibitor.  
       The present study was designed to build upon these previous findings and 
further confirm that the Hs578t breast cell line could not be sensitized to radiation 
through autophagy inhibition. Time course studies showed a reduction of viable cell 
number upon irradiation of Hs578t breast tumor cells and that both autophagy and 
senescence were induced.  Acridine orange staining was used to examine the 
acidic vacuole formation while β-galactosidase staining indicated the promotion of 
senescence. Flow cytometry was used to quantify both autophagy and senescence. 
Inhibition of autophagy using pharmacological inhibitors such as ammonium 
chloride, or genetic silencing of autophagy by beclin1, which is a protein initiator of 
autophagy, did not sensitize Hs578t breast tumor cells to irradiation. It shows from 
these studies that autophagy is not necessarily cytoprotective in all breast cancer 
cell lines, which should be considered in current clinical trials designed to sensitize 
tumor cells to chemotherapy and radiation through inhibition of autophagy. 
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Section 1 
Introduction 
1.1 Cancer: 
     The body is comprised of billions of living cells that have the capability to grow, 
multiply and die in an organized manner. [1] Cancer is defined as cells growing 
abnormally and out of control. Cancer can be benign when it only spreads locally 
and does not invade other tissue, or it can be malignant if it metastasizes. 
Because there are many different types of cancer, treatments strategies will also 
differ. In general, cancer should be treated immediately upon diagnosis as 
otherwise it will lead to death. 
       In 2013, about 1,660,290 new cases of cancer were expected to be 
diagnosed and about 580,350 Americans were expected to die of cancer. [1] This 
leads to cancer being the second most common cause of death in the US.  
      There is no single cause of cancer; there are many genetic and environmental 
factors that might interact to cause cancer. Some types of cancer have been 
associated with environmental factors such as smoking, exposure to ultraviolet 
radiation and high-fat food. [3] Also viruses such as HPV (Human Papilloma Virus) 
have been associated with cervical and head and neck cancer. [4] Mutations in 
oncogenes, tumor suppressor genes and mis-match repair are thought to play 
central roles in the development of cancer. [5] 
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      Telomerase, the specific DNA polymerase that inserts telomere repeat 
segments to the terminations of telomeric DNA, is lacking in normal cells but 
highly expressed in human cancer cells. [5] The expression of telomerase activity is 
associated with the immortalization of cancer cells and resistance to the 
development of senescence.  
1.2 Breast Cancer 
          There are a number of different forms of breast cancer. When cancer 
originates in the ducts, it is known as ductal carcinoma and if it originates in 
lobules it is called lobular carcinoma. Inflammatory Breast Cancer is another type 
of the breast cancer that affects primarily  the skin of breast. [2]  In general breast 
cancer accounts for 22.9% of all cancers that affect women and it is more than 
100 times more common in women than in men. Survival rates for breast cancer 
differ greatly based on the cancer type, stage, treatment, and health status of the 
patient.  
        The first symptom of breast cancer is typically the feeling of a lump that 
differs from the rest of the breast tissue. Earliest cancers can be detected by a 
mammogram. [2] Breast cancer can be a hereditary disease since in the United 
States, 10 to 20 percent of patients with breast cancer have a first- or second-
degree relative with this disease. [6] 
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     Breast cancers can be classified by several categories. Each has its influence 
on the prognosis and can affect treatment response. [7] Breast cancer can be 
classified according to histopathology in which most cancers are derived from 
epithelial cells. Alternatively, it can be classified according to the stage, where 
stage 1 represents cancer that is confined to the breast and stage 4 representing 
breast cancer that has metastasized to the lymph nodes and distant organs. 
Another classification of breast cancer is according to the receptor status, as it 
may or may not have three important receptors: estrogen receptor (ER), 
progesterone receptor (PR), and HER2. The presence of the estrogen receptor 
allows cancer cells to be treated with hormonal therapies such as Tamoxifen and 
to have a better prognosis. [2] Another type of breast tumor, one that does not 
express estrogen receptor (ER), progesterone receptor (PR), or HER2, is termed 
called Triple Negative Breast Cancer. [8] 
 
 1.3 Triple Negative Breast Cancer (TNBC) 
       As indicated above, TNBC is a type of breast cancer that does not express  
the estrogen receptor (ER), progesterone receptor (PR) or human epidermal 
growth factor receptor-2 Her2/neu. [9] Triple negative breast cancers are 
considered to be high aggressive with a poor prognosis.  It accounts for 
approximately 15%-25% of all breast cancer cases and tends to  affect younger 
women, African American and Hispanic women.  
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            Great efforts have been devoted to identify novel therapeutic targets for 
TNBC; however, the heterogeneity and complexity of the biology of TNBC pose 
significant challenges to development of targeted agents. Agents that have being 
examined in clinical trials include the monoclonal antibody that targets the EGFR 
such as cetuximab, multityrosine kinase inhibitors and poly (ADP-ribose) 
polymerase (PARP) inhibitors. [10] Also anti-angiogenic therapies such as 
bevacizumab are used as adjuvant therapy for women with triple-negative breast 
cancer. [11] 
 
1.4 Current Medical Treatment. 
 
      Treatment of breast cancer can include surgical intervention, radiation, and 
chemotherapy. [2] Treatment can be alone or in combination and will depend on 
many factors such as the type and stage of the cancer, whether the cancer is 
sensitive to certain hormones, and whether the cancer overexpresses some of the 
receptors such as HER2/neu. Amplification of HER2 plays a critical role in the 
development and progression of certain aggressive types of breast cancer. [12] 
 
Surgery: Surgery is used to remove the primary tumor, whether or not it has 
metastasized. It is also used to test for cancer spread by checking  lymph nodes 
under the arm for disease inflitration. Mastectomy removes the entire affected 
breast while lumpectomy removes only the breast lump and a surrounding margin 
of normal tissue.[2] 
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Chemotherapy: Chemotherapy refers to the use of medication to destroy or slow 
the growth of rapidly multiplying cancerous cells. [2] It is considered a systemic 
form of breast cancer treatment because drugs are given intravenously or orally 
and enter the bloodstream to travel to all areas of the body’s in order to reach 
cancer cells. There are three major types of chemotherapy: neo-adjuvant which is 
used before surgery to shrink the tumor size, adjuvant which is given after surgery 
to reduce risk of recurrence, and palliative  which is given when the cancer 
spreads beyond the breast and localized lymph nodes and is used to control but 
not to cure the cancer.  Chemotherapy is given  in cycles of treatment, followed by 
a recovery period. The total chemotherapy treatment usually takes several 
months to one year, depending on the type of drugs given. [2] 
      According to the breast cancer types and the patient condition, physicians 
usually try to personalize the breast cancer treatments. Drugs that are frequently 
used for adjuvant chemotherapy in breast cancer are cyclophosphamide, 5-
fluorouracil, and taxol. [7] 
      Despite  the improvement in the diagnostic tests that are used  in early  
detection and understanding of basic molecular biology of breast cancer, around 
30% of all patients with early-stage breast cancer have recurrent disease. 
Reduction in the effectiveness of chemotherapy is often due to development of 
resistance. [7] There are several mechanisms of drug resistance in breast cancer. 
For instance, resistance to Tamoxifen, which is an estrogen antagonist that binds 
to the estrogen receptor (ER) and inactivates it, has been developed by cancer 
cells by reducing estrogen receptor  expression.[46] 
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    Hormonal Therapy: Hormonal therapy is another form of systemic therapy that 
is used as adjuvant therapy to reduce the risk of cancer recurrence. [2] Estrogen 
stimulates the growth of cancers that are positive for the hormone receptor. 
Generally about two-thirds of breast tumors are hormone receptor-positive and  
express the receptors for the hormones estrogen and/or progesterone.The 
mechanism of action of hormonal therapy  involves interfering with estrogen 
acting on breast cancer cells or lowering estrogen levels. Hormonal therapy  is not 
effective  for patients whose tumors are hormone receptor negative such as triple 
negative tumors. [2] 
        There are many drugs that are used as hormonal therapies. Selective 
estrogen receptor modulator or SERMs have estrogen-like agonist properties in 
some tissues but work as anti-estrogens in other tissues.[7] Tamoxifen is an 
estrogen antagonist that is an example of a SERM that can be given after surgery 
for 5 years to reduce the chances of recurrence of the cancer by about half, 
thereby significantly prolonging patient survival. Tamoxifen also reduces the risk 
of a new breast cancer in the other breast. [13]  
Aromatase Inhibitors (AIs) represent another form of hormonal therapy that  
interferes with estrogen production in the breast tissue of post-menopausal 
women and which are used to treat both early and advanced breast cancer. [14] 
Because of their effectiveness, AIs are the most clinically used antihormonal 
treatment for breast cancer in postmenopausal women. However, AIs are 
ineffective in pre-menopausal patients where high levels of estrogens are being 
produced in the ovaries. [14] 
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Targeted therapy for breast cancer 
    Changes in the activity of specific genes have been associated with breast 
cancer development, and researchers have been able to discover  newer drugs 
that specifically target these changes. The mechanisms of action of these 
targeted medications differ from that of standard chemotherapy drugs, and they 
often have less severe side effects. [15]  About 1 in 5 patients with breast cancer  
has high levels  of a growth-promoting protein known as HER2/neu on their 
surface. These breast cancers have a greater ability to grow and spread more 
aggressively and   a number of drugs have been developed that target this 
protein. [2] 
    Trastuzumab is a monoclonal antibody  that binds to HER2 and can help slow 
the growth of cancer cells that overexpress HER2. It may also stimulate the 
immune system to more effectively attack the cancer. [16] Trastuzumab is often 
used as adjuvant therapy for HER2-positive cancers  with chemotherapy to 
reduce the risk of  cancer recurrence. In the later course of treatment, 
trastuzumab  can be give alone, usually for a total of a year of treatment. [2] 
     Bevacizumab (also known as Avastin) is another monoclonal antibody that can 
be used in  patients with metastatic breast cancer. This antibody antagonizes the 
vascular endothelial growth factor, which is  a protein that helps tumors to form 
new blood vessels. Bevacizumab is given by intravenous (IV) infusion. It is 
commonly used in combination with chemotherapy. [17]  
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        Bevacizumab was first accepted by the US Food and Drug Administration 
(FDA) as part of the treatment for metastatic breast cancer in 2008, but is no 
longer approved for this purpose.[18] 
      Another example of targeted therapy is Everolimus, which  blocks mTOR ( the 
mammalian target of Rapamycin) which is a protein in cells that normally 
promotes  growth and division. [15] By blocking mTOR,  Everolimus can prevent 
cancer cells from growing. Everolimus may also prevent tumors from forming  new  
blood vessels. It is approved to treat advanced tumor cells and earlier stage 
breast cancer, with other hormone therapy drugs, and in combination with other 
treatments. Bevacizumab is not effective in  patients with triple-negative  breast 
cancer (TNBC) because of the lack of targeted therapy for these patients. [15] 
 
Radiation therapy:  
     Radiation therapy involves the medical use of ionizing radiation to control or kill 
cells in cancer treatment. [20] If the cancer is localized in one part of the body, then 
radiation therapy may be curative, or as  adjuvant therapy  to prevent tumor 
recurrence after surgery or with chemotherapy.  The treatment goal of radiation 
therapy depends on the tumor type, location, and stage, as well as the general 
health of the patient. Ionizing radiation produces its effect by damaging the DNA 
of exposed tissue leading to cellular death.  In photon therapy, the radiation 
produces  double strand breaks which is more effective in promoting cancer death  
than  single strand breaks. [20] 
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      In the Law of Bergonie and Trebondeau, radiation is more damaging for 
rapidly dividing cells such as epithelial cells of the gastrointestinal tract than non-
dividing cells and neurons. [21] During IR exposure, both single-stranded DNA 
breaks (SSB) and double-stranded DNA breaks (DSB) occur. DSB have more 
lethal effects than SSB.[21] 
     The measure of radiation is in terms of Rads of Grays (Gy) where 100 rads is 
equivalent to 1 Gy. The radiation dose that will be administered depends on many 
factors including the stage and size of the tumor, as well as the patient’s health. 
[20]  
         In the clinic, the total doses for radiation of tumors range from 40 to 80 Gray, 
and usually these doses are given in the form of fractionated doses of 1.8 – 2 Gy 
over a period of time. [20] The rationale for using fractionated doses is to allow the 
healthy cells to recover since tumor cells are less effective in repairing damage to 
their DNA. [21] Also fractionated radiation will allow the specific cycle resistant 
tumor to enter to another cycle where they might be more radio-sensitive. With 
fractionated doses of radiation, hypoxic and more radio-resistant cells might re-
oxygenate between fractions.  
     Radiation therapy is generally not of itself painful to the patient.  However, the 
severity and longevity of side effects will depend on the organs involved in 
receiving the radiation, the co-administration of chemotherapy, and the patient’s 
health.[20]  The most common side effects of radiation are  nausea, vomiting, 
gastrointestinal ulcers, edema, abdominal discomfort, and infertility in rare cases.  
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1.5 Cellular response in Cancer: 
     Apoptosis, autophagy, necrosis, and senescence are cellular responses to 
external stresses such as radiation and chemotherapy.[22]  Cellular responses may 
equilibrate cell death with survival of cells. This balance plays a critical role in the 
ultimate decision of cancer cell fate.   
 
Apoptosis 
     Apoptosis, or type I programmed cell death, was first described by Kerr et al in 
1972. Apoptosis  is  characterized by specific morphological and metabolic 
changes of dying cells, which includes membrane shrinkage, nuclear 
fragmentation, and loss of adhesion to extracellular matrix. [23] Chromosomal DNA 
cleavage and externalization of phosphatidylserine, Annexin I and calreticulin are 
among specific biochemical abnormalities of apoptosis. In response to stress, 
cells are producing intracellular responses that initiate apoptosis and lead to cell 
death.  
     One of the most important regulators of apoptosis is the caspase family, which 
are endoproteases that hydrolyze peptide bonds and lead to activation of 
signaling pathways and ultimately apoptosis. [23] Caspases that are involved  in 
apoptosis have been subdivided according to their mechanism of action to either 
initiator caspases (caspase-8 and -9) or executioner caspases (caspase-3, -6, 
and -7). 
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         There are two basic pathways that regulate apoptosis, the intrinsic or 
mitochondrial pathway and the extrinsic or receptor-mediated pathway. [22] In the 
extrinsic pathway, Fas, which is plasma membrane death receptor, binds with its 
extracellular ligand Fas-L. Formation of Fas/Fas-L complex initiates cell death and 
recruits death domain-containing protein (FADD) and caspase 8 to form the 
death-inducing signaling complex (DISC). DISC activates pro-caspase-8 and pro-
caspase-3.  
        In the intrinsic pathway, activation of apoptosis is regulated by mitochondrial 
pro-enzymes. [22] When the cell is stimulated by external or internal stimuli, outer 
mitochondrial membranes become permeable and cytochrome c  is then released 
into the cytosol. The release of cytochrome leads to recruitment of pro-caspase-9 
and apaf-1 to form the apoptosome which downstream activates the caspase 9/3 
signaling cascade of apoptosis.  
       In many types of cancer cells, the Bcl 2 family proteins are overexpressed. 
Bcl2 is one of the major regulators of apoptosis.[22]  Reduction of  Bcl-2 expression 
is permissive for  apoptotic responses to anticancer drugs, while overexpression  
of Bcl-2 leads to resistance to chemotherapeutic drugs and radiation therapy. The 
Bcl-2 family consists of of pro-apoptotic members such as Bax, Bak, Bad, Bcl-XS, 
Bid, Bik, Bim and Hrk, plus further anti-apoptotic members such as Bcl-2, Bcl-XL, 
Bcl-W, Bfl-1 and Mcl-1.  
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        Another important proapoptotic factor and tumor inhibitor is p53, which acts 
as a tumor suppressor preventing cancer.  Since p53 activates apoptotic cell 
death by promoting a number of positive regulators of apoptosis, the antitumor 
effects of many chemotherapeutic agents may be mediated by targeting p53-
related signaling pathways. [24] 
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Ouyang L et al (2012) 
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Autophagy 
 
       The process of autophagy was first revealed by Keith R. Porter and his 
postdoctoral student Thomas Ashford. [28]  It involves the catabolism of 
unnecessary or dysfunctional cellular components, and is initiated by the 
formation of autophagosomes, double membrane-bound structures surrounding 
cytoplasmic macromolecules and organelles, designated for recycling. [26] 
Autophagy can promote cellular survival during starvation by maintaining cellular 
energy levels. [28]  It plays a crucial role in a homeostasis by controlling 
physiological processes including cell differentiation, cell survival and death. [22] 
 
      The autophagy process consists of different steps, including induction step, 
cargo recognition and selection, vesicle creation, autophagsome-vacuole union, 
and analysis of the cargo followed by release of the degradation yields back into 
the cytosol. [22] Different ATG (Autophagy related genes) are essential in these 
steps. In the induction step, starvation or rapamycin treatment leads to activation 
of the Unc-51-like kinase 1 (ULK1) and -2 (ULK2), also FIP200 (the focal 
adhesion kinase family-interacting protein of 200 kD). FIP200 forms a complex 
with ULKs and mammalian Atg13 and identifies to the phagophore.  
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      In the cargo recognition step,  p62/sequestosome 1 (SQSTM1) binds both 
poly- or mono-ubiquitin through its ubiquitin-associated (UBA) domain and the 
mammalian Atg8 homolog, LC3 (microtubule-associated protein 1 light chain 3). 
[27] In the formation of autophagosome step, multiple Atg proteins are recruited to 
the phagophore to take part in  autophagosome formation. After completion of 
autophagosome formation, Atg8 attached to the outer membrane is cleaved from 
PE (phosphatidylethanolamine) by Atg4 leadsing to autophagsome-vacuole 
fusion.  
       The complete process of autophagy is called Autophagic flux.  To confirm the 
autophagic flux, p62 may be used as a marker. [27] p62 accumulates when  
autophagy is inhibited, and degraded levels of p62 can be observed when 
autophagy is induced 
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    One of the crucial regulators of autophagy is p53, which is the tumor 
suppressor gene most commonly mutated in human cancers. p53 has a dual 
effect on autophagy. [25] One way for p53 to induce autophagy is through activation 
of AMPK kinase, which leads to activation of TSC1 and TSC2 kinases, and to the 
acute inhibition of mTOR kinase (mammalian target of rapamycin).  Kroemer et al 
reported that cytoplasmic but not nuclear p53 has the autophagy-inhibiting 
function. [47] 
      Autophagy has many different roles in cancer. [29] In the literature, it has been 
shown that chemotherapeutic drugs and radiation can lead to a cytoprotective 
form of autophagy in tumor cells, in which the sensitivity of tumor to radiation or 
chemotherapy is increased upon inhibition of autophagy. This increased in 
sensitivity after blockage of autophagy occurs by promoting apoptosis. 
Cytoprotective autophagy has its clinical implication, in that theoretically a patient 
can take an autophagy inhibitor such as chloroquine that leads to sensitization of 
tumor cells to radiation or chemotherapy.  
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      Another (lack of) function of autophagy is to be non-cytoprotective, in which 
inhibition of autophagy does not sensitize tumor cells to radiation or 
chemotherapy. [29] Cytotoxic effect is the third role of autophagy in cancer that 
leads to either killing of cells of itself or acts as a precursor to apoptosis. The main 
basic difference between cytotoxic and cytoprotective autophagy is that upon 
inhibition of autophagy in cytoprotective autophagy, the cells are sensitized to the 
treatment, while when cytotoxic autophagy is inhibited, the cells become less 
sensitive to the treatment.  
 
       The fourth function of autophagy in cancer is Cytostatic Autophagy. [29] In our 
laboratory, it has been shown that the combination therapy of vitamin D and 
radiation leads to a more pronounced growth inhibition of non–small cell lung 
cancer cells than for radiation alone. Also pharmacologic inhibition of autophagy 
protects the cells from the sensitization to radiation by vitamin D. The relationship 
of cytostatic autophagy with senescence is currently under investigation in our 
laboratory.  
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1.5.3 Senescence 
                  Cellular senescence refers to the irreversible arrest of cell proliferation that 
occurs when cells experience oncogenic-induced stress or other forms of stress 
such as radiation and chemotherapy. [30] Since there is no known physiological 
inducer that has the ability to stimulate senescent cells to reenter the cell cycle, 
the senescence is considered irreversible. [32] One of the reasons why normal cells 
do not proliferate indefinitely is dysfunction of telomeres. Telomeres cap the ends 
of linear chromosomes and protect them from degradation or fusion by DNA-
repair processes. In some cases, telomeres become short and dysfunctional 
which trigger a classical DNA damage response (DDR). DNA damage and 
dysfunctional telomeres induce p16, which acts as a tumor suppressor that is 
implicated in the prevention of cancers and offers a second obstacle to prevent 
the growth of cells.  
 
             Maintenance of  the senescence growth arrested state is controlled 
mainly by either or both of the p53/p21 and p16INK4a/pRB tumor suppressive 
pathways. [31] Both pathways have multiple upstream and downstream regulators. 
p53 and pRB are transcriptional regulators. p21 is a downstream effector of p53, 
while  p16INK4a is a positive upstream regulator of pRB effectors. p21 and pRB 
are cyclin-dependent kinase inhibitors and strong negative regulators of cell cycle 
progression.  
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1.5.4 Necrosis 
        Necrosis is a result of cell injury that leads to the premature death of cells by 
autolysis. Infection, toxins, or trauma are external factors that lead to necrosis. [33] 
During necrosis, cells initial swell then the plasma membrane breakdowns, and 
cells are rapidly lysed. Necrosis can be tested in vitro by measuring permeability 
of the cell plasma membrane to vital dyes like trypan blue, and efflux of cytosolic 
enzymes such as lactate dehydrogenase, or creatine kinase. 
 
        Binding of death ligands such as TNFa, TNF-related apoptosis-inducing 
ligand (TRAIL) and Fas ligand (FasL) to their receptors leads to assembly  of 
caspase-8 and receptor-interacting serine threnoine kinase RIP1and RIP3. The 
RIP family plays a critical role in necrosis and leads to stimulation of metabolic 
enzymes like glycogen phosphorylase (PYGL), glutamate-ammonia ligase (GLUL) 
and glutamate dehydrogenase 1 (GLUD1). [34] Enhancement of metabolic 
enzymes is accompanied by production of reactive oxygen species (ROS) which 
is dependent on the NADPH oxidase to forms complexes with the adaptor 
molecules such as Tumor necrosis factor receptor type 1-associated DEATH 
domain protein (TRADD). 
 
 
 
 
 
 32 
 
  
Ouyang L et al (2012) 
 33 
1.5.5 Mitotic catastrophe 
              The term mitotic catastrophe is defined as incorrect entrance of cells into 
mitosis which can be caused by chemical or physical stresses. [35] Agents that 
affect the stability of microtubules, anti-cancer agents, and ionizing radiation are 
considered to trigger mitotic catastrophe. Cells that undergo mitotic catastrophe 
are characterised by abnormalities of chromosome segregation.  
 
        Mitotic catastrophe is characterized by elevation of cyclin B1 which is a 
regulatory protein involved in mitosis, activation of p53 which is a  tumor 
suppressor protein, persistent activation of SAC (Spindle- assembly checkpoint) 
which inhibits anaphase causing chromosome missegregation,  and caspase-2 
activation. [35] 
 
1.6 Previous studies 
       In our laboratory, it has been shown that irradiation of p53 wild type, and 
estrogen receptor-positive MCF-7 and ZR-75-1 breast tumor cells induce 
autophagy. The autophagy produced by radiation alone was found to be 
cytoprotective in that both pharmacological and genetic inhibition of autophagy 
increased sensitivity to radiation. The combination therapies of vitamin D3 and 
radiation promote cytotoxic autophagy that upon inhibition the radio-sensitization 
by vitamin D is markedly attenuated. [36] [38] 
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         It has been shown in much of the current literature that the cellular 
response to radiation in many cell lines is that of autophagy. [37] It has been 
shown in our laboratory that the inhibition of autophagy does sensitize MCF-7 
and ZR-75 breast tumor cells to radiation. [36] However, this is not necessarily the 
response in all breast cell lines. In the 4T1 syngeneic murine breast tumor cells 
could not be sensitized to radiation in vitro by using pharmacological inhibitor of 
autophagy with chloroquine treatment, by silencing of the autophagy- related 
gene Atg12, or by chloroquine in vivo. [49]  Also in Hs578t cells, which are a 
mutant p53 triple negative cell line, pharmacological autophagy inhibition did not 
increase radiation sensitivity. 
        Upon irradiation, Hs578t cells undergo autophagy; however, the combination 
of radiation with the autophagy inhibitor, chloroquine, does not sensitize this cell 
lines to radiation. Also, Hs578t cells show minimal apoptosis upon radiation alone 
and furthermore apoptosis does not increase with autophagy inhibition. 
(Chakradeo S under revision) 
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1.7 Hypothesis 
    Since previous data using pharmacological inhibition of autophagy shows that 
the Hs578t cell line does not become sensitized to radiation, the effect of 
autophagy inhibition on radiation sensitivity using another pharmacological 
inhibitor and genetic approaches were recommended to be performed. 
(Chakradeo S under revision). In addition, to interfere with autophagy, beclin 1 
was silenced using siRNA techniques.  
 
     Based on previous results in Hs578t, the hypothesis for this project was that 
Autophagy is a general response of breast cancer cells to radiation, but that 
inhibition of autophagy may not sensitize breast tumor cells to radiation (non-
protective autophagy). 
Our aims were: 
AIM 1: Evaluation of the response of Hs578t to radiation 
A- Determination of the effect of radiation on autophagy 
B-Determination of the effect of radiation on apoptosis 
C-Determination of the effect of radiation on senescence 
AIM 2: Inhibition of autophagy genetically and pharmacologically 
A-Assessment of the effect of autophagy inhibition on radiation sensitivity 
B- Assessment of the effect of autophagy inhibition on senescence 
C- Assessment of the effect of autophagy inhibition on apoptosis 
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Section 2: Materials and Methods 
2.1 Material: 
     MEM Alpha media- L glutamate was purchased from Gibco. Trypsin-EDTA 
(0.25% trypsin, 0.53 mmol EDTA-4Na) was obtained from HyColne. PBS (pH=7) 
was obtaining from Gibco. X-gal (5-bromo chloro-3) was purchased from Fermenas 
Life Sciences. Fetal Bovine Serum was obtained from Serum source international. 
Acridine Orange was purchased from Invitrogen. 
2.2 Cell lines: 
      Breast tumor cells Hs578t were obtained from American Type Culture collection 
(ATCC). Hs578t cells were developed to silence the expression of Beclin1. The 
lentiviral shRNA constructs to target Beclin-1 were kindly provided by Dr. Hisashi 
Harada (Virginia Commonwealth University, VA, USA). The shRNA constructs were 
transfected into 293T cells along with lentiviral packaging plasmids. The lentivirus 
shed into the medium was then used to infect the breast tumor cells. The retrovirus 
pBp-RNA expressing constructs were kindly provided by Dr. Wataru Nakajima 
(Nippon Medical School, Kawasaki, Japan). The constructs were transfected into 
293T cells along with the packaging plasmids. The retrovirus shed into the medium 
was collected and used to infect Hs578t cells. 
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2.3 Cell Culture and Treatment: 
      Hs578t cells were grown from frozen stocks in MEM-alpha supplemented with 
20% FBS, and penicillin/ streptomycin (0.5ml) in 100 ml medium. All cells were 
maintained at 37°C under a humidified 5% CO2 atmosphere. Cells were kept in T75 
flasks (Cellstar), sub-cultured and trypsinized with (0.25% trypsin, 0.03% EDTA) for 
4- 6 minutes upon reaching confluence and then deactivated with complete MEM 
alpha media. Prior to any experiments, cells were examined by microscope for any 
fungal and bacterial infections. 
 
2.4 Cell Viability: 
      Trypan blue exclusion dye was used to identify viable cells. Cells were plated in 
triplicate at a density of 6,000 to 10,000 cells per well and allow to adhere 
overnight. The following day, cells were treated with ammonium chloride, CQ, or 3-
MA for 3 hours and then followed by a radiation dose 5x2 Gy. After radiation, media 
was changed and then cells were counted at various time points. Trypsin (0.25% 
Trypsin-EDTA) was added to cells and was incubated for 5-7 min at 36 C0. Then 
cells were stained with Trypan Blue (0.4% Trypan Blue).  Haemacytometer with 
phase contrast microscopy was used to count cells on Days 1, 3, 5, and 7 post-
radiation. 
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2.5 MTT Assay To determine the effective dose of Ammonium Chloride 
     The MTT assay was used to determine the effective dose of ammonium chloride 
for further experiments. Cells were plated in 96 well plates at a density of 5,000 
cells/well in 200µL of MEM alpha Medium. Cells were allowed to adhere to the 
plates overnight and then treated with different doses of ammonium chloride. The 
doses of ammonium Chloride ranged from 1mM-10mM. Cells were incubated with 
drug for 72 hours. Then media was aspirated and cells were incubated for 3 hours 
with the MTT solution (2mg/ml PBS) at 37 C0. After removal of the MTT solution, 
autoclaved DMSO was added and plates were shaken for 10 min.   
 
     In MTT assay, MTT dye ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) becomes reduced to an insoluble formazan inside living cells. DMSO was 
used as solubilizing agent to dissolve insoluble purple formazan product into a 
colored solution. Then Absorbance was read at 490 nm using (KC Junior software, 
EL800 Universal Microplate Reader). 
 
2.6 Clonogenic Survival Assay: 
    To evaluate the ability of a single cell to form a colony, clonogenic assay was 
used. In triplicate plates, cells were plated at a density of 150 cells per well. After 14 
days, cells were fixed with 100% methanol, air-dried and stained with 0.1% v/v 
crystal violet (Sigma 3886) 
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2.7 Evaluation of Autophagy by Acridine Orange Staining 
    10,000 cells were plated in 6-wells plates and allowed to adhere for 24 hours 
prior to being treated and irradiated. At various time points at day 1, 3, 5, and 7 
post-radiation, media was removed and cells were washed twice with PBS. Acridine 
orange dye was prepared in the dark at a dilution of 1 to 10,000 of media and 
incubated with cells for 15 minutes. Cells then were washed with PBS. Fluorescent 
micrograph images were taken using an inverted fluorescence microscope 
(Olympus). Increased numbers of acidic vesicular organelles were used as an 
indication of autophagy. 
2.8 Evaluation of Senescence by Beta Galactosidase Staining Assay 
      The state in which cells stop growing but stay metabolically active is called 
senescence or biological aging. -Galactosidase staining is used to detect the 
senescence after exposure of cells to radiation. In senescence B-galactosidase 
enzyme is overexpressed and cleaves the substrate X-Gal. Cells were plated and 
allowed to adhere overnight then were treated and radiated with dose 5x2 Gy. At 
different time points on Day 1, 3, 5, and 7 post radiation, cells were washed twice 
with 1XPBS and fixed with fixing buffer that consists of 0.2 glutaraldehyde/2% 
formaldehyde for 10 minutes followed by aspiration of the fixing solution. Cells were 
washed twice by 1XPBS followed by adding staining buffer which consists of 1 
mg/mL 5-bromo-4-chloro-3-inolyl-β-galactosidase in dimethylformamide (20 mg/mL 
stock), 5 mM potassium ferricyanide, 150 mM NaCl, 40 mM citric acid/sodium 
phosphate, 2 mM MgCl2. Staining buffer was incubated with cells overnight in CO2 
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incubator to maintain pH of solution at 6. On the next day, cells were washed with 
1XPBS and images where taken using light microscope. 
 
2.9 Western Immunoblotting 
A- Protein Collection 
   Westren immunoblotting is used to indicate the expressions of different proteins. 
To isolate proteins, cells were plated at cell density of 70,000-100,000 cells per 
10mm cell culture dish. Then cells were treated with the appropriate treatment and 
washed with 1XPBS at assigned time points. After washing with PBS, 100 to 500 µl 
of lysis buffer (1:100 phosphatase inhibitors and 1:50 protease inhibitors suspended 
in M-PER mammalian protein extraction reagent (Thermo scientific #78501) was 
added for 5 minutes. The lysate was then centrifuged for 5 minutes at 10,000 rpm. 
B-Determination of Protein Concentration by using Bradford method 
       Bradford reagent (Bio-Rad 500-0205) is used in the Bradford method to 
determine the concentration of proteins. 20 µg of equal aliquots of total cell lysate 
was loaded onto a polyacrylamide gel (10-12% based on the molecular weight of 
proteins that being analyzed). By using SDS-PAGE running buffer and 170 
milliamps constant current, proteins were separated for 1-2 hours. Then proteins 
were transferred onto a PVDF membrane for 1.5 hours and washed 4 times with 
PBS containing 0.01% Tween for 15 minutes in each time. 
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C-Immunoblotting 
        The membrane was blocked with TBS-Tween buffer containing 5% dry milk for 
0.5 hour. Then primary antibody was added on the membrane and left overnight in 
4 C0. The following day, the primary antibody was washed out with TBS-Tween 
buffer for three times each for 15 minutes. Then secondary antibody was added 
and incubated with membrane for one hour at room temperature and then washed 
with TBS-Tween buffer. West Femto Maximum Sensitivity substrate (Thermo 
Scientific # 34095) and Premium quality X-Ray films (PHENIX) were used to 
develop the membrane. The dilution of primary antibody was 1:1000 in blotto and 
the dilution of secondary antibody and beta- actin antibody were 1:5000 in blotto. 
 
2.10 Flow cytometer Analysis (FACS) 
2.10.1 Quantification of acridine orange staining by flow cytometry for 
autophagy 
       FACS analysis was used to quantify the amount of autophagic vacuoles which 
are positively stained with acridine orange staining. After radiation of the cells for 
three days, cells were collected and suspended with acridine orange staining 
solution of 1 in 10,000 dilution in PBS for 10 minutes. In FACS analysis, for each 
gated region at least 10,000 cells should be collected. 
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2.10.2 Quantification of β-galactosidase staining by flow cytometry for 
Senescence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
       Confluent plates with hs578t cells line were treated with radiation for three days 
and on the day of staining cells were incubated with 100 nM of bafilomycin A1 in 
fresh medium to induce lysosomal alkalinization and left incubated at 37C0 and 5% 
CO2 for 1 hour. After incubation, C12FDG working solution was added to each well 
in amount to make the final concentration 33 μM and was continued incubation for 
another 1 hour. Media was then aspirated and cells were washed twice with PBS. 
Cells were harvested and collected for centrifugation at speed 1500 rpm and 
resuspended in PBS. C12FDG is a substance that is hydrolyzed by upregulated β-
galactosidase enzyme and becomes fluorescent at wavelength of 500–510 nM. 
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Section 3: Results 
3.1 Influence of Radiation on the growth of Hs578t breast tumor cells 
     As described in the Introduction, radiation is used as adjuvant therapy in breast 
cancer to eradicate any remaining cancer cells post-surgery. Fractionated 
radiation doses are used in the clinic, where patients receive multiple small doses 
of 2 Gy. Previous studies from our laboratory have shown that radiation promotes 
protective autophagy in MCF-7 and ZR-75 breast tumor cells and that 
pharmacological or genetic inhibition of the autophagy induced by radiation leads 
to growth suppression and cell death, primarily through apoptosis. [36] [38] In 
contrast, the 4T1 syngeneic murine breast tumor cells could not be sensitized to 
radiation in vitro by using pharmacological inhibitor of autophagy with chloroquine 
treatment, by silencing of the autophagy- related gene Atg12, or by chloroquine in 
vivo. [49] 
 
       In this study, cells were plated, irradiated over period of three days, and then 
counted on Days 1, 3, 5, and 7-post radiation. In Figure 3.1, irradiated cells show 
initial cell death with slight recovery from days 3 to day 5 but primarily growth 
arrest. The results represent the average of three experiments with standard 
errors. 
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Figure 3.1 Effect of radiation on viable cell numbers. Upon radiation with 5 X 2 Gy, Hs578t 
cells showed growth arrest post day 5 of radiation. In each experiment, triplicates were 
used. Three different experiments were done to confirm the results. (* p value< 0.05 
compared IR  to control using ANOVA followed by tukey)  
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3.2 Effect of radiation on Hs578t breast tumor cells. 
      Autophagy is a homeostatic catabolic process that degrades impaired proteins 
and organelles and recycles them to sustain metabolic activity. Autophagy has a 
different effects in cancer, one role as tumor suppressor by preventing the 
accumulation of mutant proteins and organelles, and the other role 
(Cytoprotective) helping the existing tumor cells to survive by provide them with 
nutrients and metabolic precursors. [40] Previous studies from our lab have shown 
that in MCF-7 breast tumor cells radiation induces a cytoprotective autophagy 
because interference with that autophagy leads to growth suppression and cell 
death. [38] 
 
       Acridine orange staining was used to evaluate the effect of radiation on 
autophagy in Hs578t breast tumor cells as it is widely used to detect the presence 
of autophagic vacuoles. Acridine orange is a lysomotropic dye that becomes 
trapped upon entering acidic compartments. Under low pH conditions, Acridine 
orange emits orange light when excited by blue light. 
       In Figure 3.2, it is clear that the Hs578t breast cancer cells have minimum 
basal autophagy while irradiated cells showed an increased acridine orange 
staining and development of the orange colored puncta, which is indicative of the 
induction of autophagy. Serum starved cells were used as positive control. 
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 CONT         Day 3 post radiation                                                           IR Day3 post radiation 
 
IR Day 7 post radiation                                                        Serum starved positive control   
Figure 3.2: Induction of autophagy in Hs578t cells after radiation. Autophagy induction was 
performed using Acridine orange staining on day 1,3,5, and 7 post radiation with 5X2 Gy. 
Three different experiments were done to confirm the results. 
 47 
3.3 Quantification of Autophagy upon Radiation Using Flow Cytometery 
       Another technique that is used to evaluate the autophagy is the quantitation 
of acidic vacuoles by Flow Cytometery. In this experiment, cells were plated, 
irradiated over a period of three days, and acidic vacuoles were quantified on Day 
1, 3, and 5-post radiation. 
 
        In Figure 3.3, Hs578t control cells show minimum basal autophagy, while 
irradiated cells show the promotion of autophagy. The same experiment was 
repeated three times and in all three times statistical difference were observed 
between irradiated cells and control cells. Therefore it appears that irradiation of 
Hs578t breast tumor cells promotes autophagy.  
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Figure 3.3 Quantification of radiation induced autophagy. Hs578t cells were plated and  
irradiated with fractionated radiation (5×2Gy) and then were analyzed using Flow cytometry 
on days 1,3, and 5 post radiation. In each experiment, triplicates were used. Three different 
experiments were done to confirm the results. (* p value< 0.05 compared IR  to control 
using ANOVA followed by tukey). AVO= acidic vesicular organelles. 
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3.4. Induction of senescence in irradiated Hs578t cells.  
       Cellular senescence is a phenomena in which a cells stop to divide, but stay 
metabolically active. It has been reported that ionizing radiation promotes 
senescence in both normal and tumor cells. [30] Our laboratory has previously 
reported the induction of accelerated senescence by ionizing radiation and that 
this is largely p53 dependent. [39] 
     The Hs578t breast cell line is mutant in the tumor suppression protein, p53. [48] 
The β galactosidase-staining assay is used to distinguish proliferating and 
senescent cells. In senescent cells, beta galactosidase enzyme is overexpressed 
and upon adding x-gal which is a chromogenic substrate to the cells, - β 
galactosidase enzyme cleaves the x-gal and gives insoluble blue substance at pH 
6. 
        In Figure 3.3, there is -gal staining upon radiation of Hs578t breast cells, 
which suggests that induction of senescence upon radiation is not dependent on 
functional 53 at least in Hs578t cells. 
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Figure 3.4: Staining of the cells using X-gal shows induction of senescence upon 
irradiation of Hs578t breast cell line. Three different experiments were done to confirm 
the results. 
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3.5 Quantification of Senescence upon Radiation Using Flow Cytometery 
      The flow cytometry method is extremely useful in quantitative analysis of 
cellular senescence phenomenon. This flow cytometric analysis is able to detect 
the hydrolysis of 5-dodecanoylaminofluorescein di-β-D-galactopyranoside 
(C12FDG), a membrane-permeable and nonfluorescent substrate of β-
galactosidase, which, upon cleavage, stays inside the cytosol and produces green 
fluorescence. Flow Cytometery  allows estimation of the enzyme activity and also 
provides quantitative information on the population size of SA β-Gal-positive 
cells.[51] 
 
        In figure 3.5, irradiated cells show promotion of senescence as compared to 
control. Same experiment was repeated three times and in all three times 
significant differences were observed between irradiated cells and control cells. 
Therefore it appears that irradiation of Hs578t breast tumor cells promotes 
senescence.  
 
 
 
 
 
 
 52 
 
 
FACS Analysis of Senescence After Radiation 
Days Post-Radiation 
Day 1 Day3 Day5 Day 7
%
 o
f 
S
e
n
e
s
c
e
n
t 
c
e
ll
s
 
0
20
40
60
80
100
Hs578t control cells 
IR 5*2 GY
 
 
 
 
 
 
 
 
* 
* * 
* 
Figure 3.5 Quantification of radiation induced senescence .Hs578t cells were plated and irradiated 
with fractionated radiation (5×2Gy) and then were analyzed using Flow cytometry on days 1, 3, 5 
and 7 post- radiation. In each experiment, triplicate samples were used. Three different 
experiments were done to confirm the results. (* p value< 0.05 compared IR to control on 
Day 7 using ANOVA followed by tukey)  
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3.6  Pharmacologic and Genetic Inhibition of Autophagy 
3.6.1 Determination of the effective dose of Ammonium Chloride 
 
       It has been shown that autophagy might lead to cancer cell resistance to 
chemotherapy and radiation treatment. Inhibition of autophagy can lead to the 
sensitization of resistant cancer cells to anticancer treatment. [40] 
    Inhibition of autophagy can be performed genetically and pharmacologically. 
There are many different chemical agents that can inhibit autophagy such as 
chloroquine which is used clinically, 3 methyl adenine, bafilomycin and ammonium 
chloride. Also silencing of autophagy related proteins such as Atg5, Atg7 and 
beclin1 leads to inhibition of autophagy. 
         In our experiments, ammonium chloride has been used as an example of a 
pharmacological autophagic inhibitor. Ammonium chloride is an organic 
compound that is capable of inhibition of the fusion of autophagosome with the 
lysosome in the last step of degradation of the autophagosome contents. [41] In 
order to use ammonium chloride in the experiments, non-toxic doses were first 
determined using the MTT assay. Based on the previous literature, studies have 
shown that 10 mM is an effective dose that inhibits autophagy. [41] In figure 3.6, 
the 10 mM ammonium chloride showed no significant differences between control 
and NH4Cl treated cells.   
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Figure 3.6.  Determination of effective dose of ammonium chloride using the MTT 
assay. The dose of 10 mM ammonium chloride has relatively low toxicity profile. The 
experiment was repeated twice and the results given are the average of two 
experiments with standard Errors. No statistical differences were detected between 
control cells and cells treated with 10 mM NH4CL.  
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3.6.2 Effect of the autophagy inhibitor, ammonium chloride (NH4CL),  on 
colony formation  
 
         Clonogenic survival assays study the ability of a single cell to form a colony. 
Cells were plated in triplicate in six wells tissue culture dishes at a density of 150 
cells per well and allowed to grow for 10-14 days. 
 
       The clonogenic survival assay in Figure 3.7 indicates lack of sensitization of 
Hs578t cells to radiation even after inhibition of autophagy. Two conditions, IR 
(5*2 Gy) and IR + NH4CL were compared to asses statistical significance. The 
experiment was repeated three times and in all three times, no statistical 
difference was observed between irradiated cells and cells treated with IR and 
NH4Cl (10 mM) in their colony forming abilities. It can be said here that Hs578t 
cells treated with IR when also treated with NH4Cl do not become sensitized 
which is in accordance with our previous data. Therefore it appears that Hs578t 
breast tumor cells may not be using autophagy as a mechanism to survive. Hence 
it can be said that the role of autophagy here is a non-cytoprotective role.  
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49-27. Bristol M.L et al (2013). Autophagy inhibition for chemosensitization 
and radiosensitization in cancer: Do the preclinical data 
support this therapeutic strategy? J. Pharmacol. Exp. 
Ther. 2013;344:544–552. 
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Figure 3.7 Clonogenic  survival assay. Ammonium Chloride (10 mM) does not sensitize 
Hs578t breast tumor cells cells to radiation.  In each experiment, triplicate samples were 
used. Three different experiments were done to confirm the results. (* p value< 0.05 IR 
compared to control using ANOVA followed by tukey) (No statistical differences is 
observed between IR treated cells alone or combination of IR and NH4CL ) 
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3.6.3 Ammonium Chloride was effective in inhibition of autophagy based on 
Acridine orange staining 
   The findings in the previous figure are not consistent with much of the literature 
relating to autophagy. It was therefore necessary to confirm that the treatment 
indicated actually was effective in inhibiting autophagy in the Hs578t cells. 
Staining of vacuoles with orange is an indication of induction of autophagy while 
yellowish color shows inhibition of autophagy since ammonium chloride interferes 
with the acidity of the lysosomes. 
 
          In Figure 3.8, control cells show a low basal level of autophagy, while 
irradiated cells undergo induction of autophagy. In cells treated with ammonium 
chloride, it is clear that autophagy has been inhibited as indicated by the yellowish 
color. Inhibition of autophagy by NH4CL occurs in the last step, this explains why 
there are many vacuoles that stained with the yellowish color.  
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CONTROL Day 3 post-Radiation                NH4CL 10 mM    Day 3 post-Radiation 
 
IR  5 X 2 GY   Day 3 post-Radiation               IR+NH4CL    Day 3 post-Radiation 
 
 
 
 
 
 
 
 
Figure 3.8  Determination of the inhibition of autophagy by 10mM Ammonium chloride using Acridine 
orange staining.  Three different experiments were done to confirm the results. All images have 
the same magnification 20X.  
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3.6.4 Silencing of Beclin1  
       One classical strategy for interfering with autophagy is by silencing of 
autophagy related genes. Consequently, we developed an Hs578t breast cell line 
(Hs578t/Beclin-) in which Beclin was silenced. Beclin-1 and its binding partner 
class III phosphoinositide 3-kinase (PI3K), are essential for the initiation and 
formation of the autophagosome in autophagy. [22] 
 
 
          In Figure 3.9 , western blotting indicates a significant decrease in the levels 
of Beclin1 as compared to control. 
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Figure 3.9 Western Immunobloting to determine silencing level of Beclin1. 
Experiment was repeated twice.  
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3.6.5 Effect of Beclin1 Silencing on radiation sensitivity of Hs578t breast 
tumor cells 
          To determine the effect of autophagy inhibition on sensitization of Hs578t 
cells to radiation, beclin 1 was silenced and both wild type and beclin-1 silenced 
Hs578t cells were irradiated with 5X2 Gy for three days. Then, the number of 
viable cells was counted. Figure 3.10 indicates that genetic inhibition of autophagy 
does not sensitize Hs578t cells to radiation. 
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Figure 3.10 Cell viability assay shows that silencing of Beclin1 failed to sensitize Hs578t cells 
to radiation. In each experiment, triplicate samples were used. Two different experiments were 
done to confirm the results. (* p value< 0.05 compared IR to control using ANOVA followed by 
tukey) (No statistical differences between IR and combination IR+Beclin-/-) 
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3.6.6 Effect of the Beclin1 Silencing on the ability to form colonies 
         Wild type Hs578t breast tumor cells and Hs578t/beclin1- were plated at low 
density 150 cells per well, then irradiated for three days with radiation dose 5 X 2 
Gy. Plated cells were incubated for 10-14 days. Number of colonies in each well 
was counted and calculated as a percentage of control. Figure 3.11 provides 
further confirmation that silencing of Beclin 1 does not sensitize Hs578t breast 
tumor cells to radiation. 
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Figure 3.11 Clonogenic  survival assay by silencing Beclin-1  does not sensitize Hs578t 
breast tumor cells cells to radiation. In each experiment, triplicate samples were used. Four 
different experiments were done to confirm the results. (* p value< 0.05 compared IR  to 
control using ANOVA followed by tukey)  
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3.6.7  Beclin1 was effective in inhibition of autophagy based on Acridine 
orange staining 
 As in the studies using NH4Cl, it was necessary to confirm that the silencing of 
beclin was effective in inhibition of autophagy. In Figure 3.12 where studies using 
control, beclin-, and combination of beclin- and irradiated cells are presented, 
there is minimum induction of autophagic vacuoles in the Beclin-1 silenced cells 
while irradiated cells have shown extensive induction of orange color as indicated 
by acridine orange staining. 
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Cont    Day 1 post-Radiation                                     Beclin-     Day 1 post-
Radiation 
 
 
IR 5*2Gy   Day1   post-Radiation                    IR+Beclin-    Day 1 post-Radiation 
 
 
 
 
 
 
Figure 3.12 Determination of the inhibition of autophagy after silencing of beclin using Acridine 
orange staining. Three different experiments were done to confirm the results and a 
representative experiment is shown. All images have the same magnification 20X.  
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3.6.8 Degradation of p62 representing autophagic flux  
         P62 is a protein associated with the nuclear envelope. The complete 
process of autophagy is called autophagic flux.  To confirm autophagic flux, p62 
may be used as a marker. [27] p62 accumulates when autophagy is inhibited, and 
decreased levels can be observed when autophagy is induced. [27] LC3 is a 
receptor for p62. When p62 binds to LC3, autophagy degradation is promoted. 
LC3 II is a microtubule-linked protein, which is transformed from LC3I to LC3 II 
once autophagy is induced. Therefore, LC3 and p62 are together autophagy 
associated proteins and broadly used as markers for autophagy. 
 Figure 3.13 shows p62 levels in control cells, beclin1-/- cells, irradiated cells and 
in irradiation in Hs578t cells where beclin-1 was silenced. While irradiated 
parental cells show degradation of p62 that indicates the induction of autophagic 
flux, p62 accumulates in the Beclin-1 silenced cells with radiation, indicating that 
autophagy has been inhibited.  
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Figure 3.13 Western Immunobloting to Assess degradation of p62.  All proteins 
were collected on Day 5 post radiation. Serum starved cells proteins were 
collected after 72 hours of plating.  
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3.6.9 Relationship between senescence, autophagy inhibition and irradiation 
in Hs578t breast tumor cells using beta galacotosidase staining. 
 
       Previous studiess have shown that there is a induction of autophagy and 
senescence upon irradiation of Hs578t cells. [45] To assess the relationship 
between autophagy, senescence and radiation, cells were plated and treated with 
different autophagy inhibitors and then irradiated with 5X2 Gy for three days. On 
days 1, 3, 5, and 7 post-radiation, beta galacotosidase staining was performed to 
evaluate senescence. 
 
Figure 3.14 confirms, as shown above, that irradiation induces senescence in the 
Hs578t cells and that inhibition of autophagy results in a reduction in the extent of 
senescence. 
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CONT  Day 1 post-Radiation                                     Beclin-/- Day 1 post-Radiation 
 
 
IR Day 1 post-Radiation                                   IR + Beclin -/- Day 1 post-radiation 
 
 
 
 
 
Figure 3.14 Beta Galactosidase staining that shows the reduction of senescence after using 
different approaches autophagy inhibitor. Three different experiments were done to confirm 
the results. All images have the same magnification 20X.  
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2.6.10 Quantification of senescence by flow cytometry for Senescence upon 
radiation and silencing of beclin-1  
        To further evaluate the relationship between senescence and autophagy 
inhibition upon radiation, senescence was quantified by FACS analysis in Beclin-1 
silenced cells that were irradiated with 5X2 Gy for three days.  
 
In figure 3.15, the irradiated cells show induction of senescence. With the 
combination Beclin-/- and irradiation, there is a reduction of the extent of 
senescence.  
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FACS Analysis of Senescence after Gene Silencing of Autophagy 
Days Post Radiation 
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Figure 3.15  Quantification of senescence. Hs578t cells were plated and  irradiated with 
fractionated radiation (5×2Gy) and then were analyzed using Flow cytometry on days 1,3, 5 and 7 
post radiation. Silencing of beclin-1 leads to reduction of senescence upon radiation. In each 
experiment, triplicate samples were used. Two different experiments were done to 
confirm the results. (* p value< 0.05 compared IR  to IR+Beclin1 -/- using ANOVA 
followed by tukey)  
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Section 4: Discussion 
   4.1 Overview 
 
    Radiation is essential as adjuvant therapy in the management TNBC. [48] One 
of the major limitations in radiation therapy is the development of resistance. In 
theory, sensitization of tumor cells to radiation can be accomplished by inhibition 
of cytoprotective autophagy. Inhibition of autophagy can be achieved by using 
the anti-malarial drug chloroquine and leads to sensitization of some breast 
tumor cell lines to radiation. [36] 
 
   Studies from our laboratory have shown that Hs578t cells are relatively 
resistant to irradiation compared to other breast cancer cell lines such as MCF7 
cells.Also in our laboratory, MCF-7 and ZR-75 breast tumors were sensitized to 
radiation upon treatment with an autophagy inhibitors such as chloroquine. [36][38]  
However, inhibition of autophagy by chloroquine fails to sensitize Hs578t breast 
cell line to radiation. (Chakradeo S et al under revision). In the current work, we 
sought to evaluate the effect of autophagy inhibition using another 
pharmacological inhibitor and genetic silencing of autophagy related genes on 
the sensitivity of Hs578t cells to radiation. 
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4.2 Response of Hs578t cells to radiation 
   Studies in our laboratory have shown that Hs578t cells are relatively resistant 
to irradiation compared to other breast cancer cell lines such as MCF7 cells. [38] 
Initial experiments were designed to identify the response of Hs578t breast tumor 
cells to radiation. When cells were irradiated with a 5×2 Gy of radiation over a 
period of 3 days, cell numbers declined between Day 1 to Day 3 and from Day 3 
to Day 7, cells undergo an apparent growth arrest. In our laboratory MDA-MB-
231 breast tumor cells upon radiation undergo apoptosis and the cells are not 
showing recovery. [50] While in Hs578t cells are slightly recovered and showed 
sustained growth arresting which indicate the radio resistance of Hs578t 
compared to other cell lines. [38] 
 
4.3 Effect of irradiation on autophagy 
          Autophagy is a catabolic process in which select cellular organelles and 
proteins are digested by lysosomal degradation. It has been shown that the 
cellular response to radiation in many cell lines is by autophagy. [40] Our studies 
using Hs578t cells demonstrated that the irradiated cells show l characteristic of 
autophagy in that there is an increase in the formation of acidic vacuoles upon 
irradiation. 
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   P62 is a protein complex linked with the nuclear envelope and its degradation 
is used as marker of autophagy flux. [27] In this study, the degradation of P62 in 
irradiated cells confirms the induction of autophagic flux by irradiation.  
 
 
4.4 Effect of irradiation on senescence 
     Several studies have shown that induction of autophagy is associated with the 
promotion of senescence in cancer cells. [45] Our observations indicate that 
irradiation induces autophagy in Hs578t breast cells line, as furthermore the time 
course study of cell viability demonstrated a sustained growth arrest pattern, 
which can be an indication of senescence. Our experiments demonstrated that 
the irradiated cells show morphological characteristics of cells that undergo 
senescence, and there is an increase in the number of cells that stained with X-
gal which is a marker for senescence upon irradiation. Our observations suggest 
that radiation induces senescence in the Hs578t breast cells line.  
 
4.5 Effect of autophagy inhibition on radiation sensitivity  
     Autophagy might be responsible for cancer resistance to chemotherapy and 
radiation treatment. Inhibition of autophagy can lead to sensitization.[40] In this 
study, several experiments were designed to determine whether autophagy 
inhibition could sensitize Hs578t breast tumor cells to irradiation.  
 
 
 79 
Previous data from our laboratory in Hs578t cells using chloroquine and 3-methyl 
adenine as pharmacological inhibitors have shown lack of sensitization in 
irradiated cells. Use of one more pharmacological inhibitor NH4CL also confirmed 
lack of sensitization. To prove that lack of sensitization is not specific to 
pharmacological inhibitors, genetic inhibition of radiation-induced autophagy was 
assessed, which confirmed lack of sensitization by genetic inhibition. The data of 
combination of irradiation and inhibitors of autophagy suggest that Hs578t cells do 
not become sensitized to irradiation. However the combination effect might 
suggest additive effect rather than sensitization. Since Sensitization is a state of 
supra additive outcome where the total effect of two agents is more than the 
additive influence of each of those agents separately  
 
 
4.6 Relationship between autophagy and senescence  
     Young et al.( 2009) reported that autophagy was an effector mechanism of 
senescence and contributed to the establishment of oncogene-induced 
senescence. Our laboratory has also generated data that senescence and 
autophagy can be dependent on each other. [45] Experiments were designed to 
study the relationship between autophagy and senescence induced by radiation 
in Hs578t cells. -galactosidase staining was used to assess the relationship 
between senescence and autophagy using different pharmacological and genetic 
inhibitors of autophagy.  
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        Data from beta galactosidase staining suggest that irradiation of Hs578t cells 
promote senescence, and that inhibition of autophagy leads to reduction of that 
senescence. Flow cytometry quantification of senescent cells confirm the same 
results. Thus , a conclusion that can be made that  in Hs578t cells, autophagy and 
senescence might be closely linked responses. 
 
         In conclusion, In MCF-7 breast tumor cells, ionizing radiation stimulated 
autophagy that was cytoprotective; pharmacological or genetic inhibition of 
autophagy stimulated by radiation resulted in growth suppression and/or cell 
killing (mainly by apoptosis). So inhibition of the cytoprotective autophagy can be 
used in clinic to sensitize the MCF-7 to radiation. However, in Hs578t breast 
tumor cells, ionizing radiation stimulated autophagy that was non-cytoprotective. 
So in order to save patients time, using the pharmacological inhibitor of autophagy 
is useless in Hs578t treatments. In order to enhance the treatment field of Hs578t 
cells, more efforts should be devoted to target the proliferative pathways like 
mTor, AKT, MAPK, and PI3K pathways.  
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Section5: 
Future Experiments  
        
  The current findings indicate that the autophagy that is induced by radiation in 
the triple negative Hs578t human breast tumor cell line appears to be non-
protective in that inhibition of this autophagy does not increase sensitivity to 
radiation. Our findings also show that this autophagy is not cytotoxic, since its 
inhibition does not reduce radiation sensitivity. 
       To further study the role of autophagy in Hs578t cells exposed to radiation, 
the influence of autophagy inhibition on radiation sensitivity should be determined 
by silencing other autophagy related protein. Since Beclin-1 is one initiator of the 
autophagy pathway, silencing another protein that has a role in the late steps of 
autophagy, such as ATG7 or ATG5 should be performed. 
        Previous data from our laboratory has shown that irradiation induces 
minimal apoptosis in the Hs578t cells, which   does not increase with autophagy 
inhibition. The utilization of additional genetic inhibitors of autophagy should 
confirm these conclusions. In addition, it would be important to further establish 
the relationship between autophagy and senescence, again with the silencing of 
additional autophagy related genes. In the long term it would be of value to 
identify the signaling elements that distinguish cytoprotective from non-protective 
autophagy. 
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